Using S-adenosylmethionine to treat alcoholic cirrhosis
S-adenosylmethionine treatment in alcoholic cirrhosis
This study is looking at how a supplement called SAMe might help people with alcoholic cirrhosis, a serious liver problem, by seeing if it can improve liver health and overall well-being compared to a placebo, and we're inviting 196 participants to join us in this friendly trial at several hospitals.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-11097467 on NIH RePORTER |
What this research studies
This research investigates the effects of S-adenosylmethionine (SAMe) on patients suffering from alcoholic cirrhosis, a serious liver condition. The study will involve a randomized, double-blind, placebo-controlled trial where participants will receive either SAMe or a placebo to assess its impact on liver health and overall mortality. The trial aims to enroll 196 participants, including those with varying severity of cirrhosis, to evaluate the potential benefits of SAMe in improving liver function and reducing inflammation. The research is being conducted across multiple centers, including Indiana University Hospital and Cedars-Sinai Medical Center.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with alcoholic cirrhosis, particularly those classified as Child class A and B.
Not a fit: Patients with cirrhosis not related to alcohol consumption or those with advanced liver disease (Child class C) may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that improves liver health and reduces mortality in patients with alcoholic cirrhosis.
How similar studies have performed: Previous research has shown promising results with SAMe in liver-related conditions, suggesting potential for success in this novel application.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Liangpunsakul, Suthat — Indiana University Indianapolis
- Study coordinator: Liangpunsakul, Suthat
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.